Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma

AR Singh, S Joshi, AM Burgoyne, JK Sicklick… - Molecular cancer …, 2016 - AACR
Abstract Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of
prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug …
被引用次数：59 相关文章

Single agent and synergistic activity of the" first-in-class" dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma

AR Singh, S Joshi, AM Burgoyne… - Molecular cancer …, 2016 - experts.nebraska.edu
Abstract Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of
prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug …

Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

AR Singh, S Joshi, AM Burgoyne, JK Sicklick… - Molecular Cancer …, 2016 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK,
and c-Myc signaling pathways are of prognostic significance in hepatocellular carcinoma …

Single Agent and Synergistic Activity of the" First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

AR Singh, S Joshi, AM Burgoyne… - Molecular cancer …, 2016 - pubmed.ncbi.nlm.nih.gov
Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of
prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug …

Single Agent and Synergistic Activity of the" First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

AR Singh, S Joshi, AM Burgoyne… - Molecular Cancer …, 2016 - europepmc.org
Abstract Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of
prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug …
[HTML] nih.gov

[HTML][HTML] Single Agent and Synergistic Activity of the" First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma

AR Singh, S Joshi, AM Burgoyne… - Molecular cancer …, 2016 - ncbi.nlm.nih.gov
Abstract Deregulated PI3K/AKT/mTOR, Ras/Raf/MAPK, and c-Myc signaling pathways are of
prognostic significance in hepatocellular carcinoma (HCC). Sorafenib, the only drug …